DOCSLIB.ORG

Event - Nalmefene Is Biotie's Big Moment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Event - Nalmefene Is Biotie's Big Moment November 05, 2010 Event - Nalmefene is Biotie's big moment Jonathan Gardner Biotie Therapies is approaching a classic make-or-break moment. Pivotal data due before the year end on its lead compound, alcohol dependence therapy nalmefene, holds the potential to pave the way for much-needed financing or much hand-wringing. The Finland company needs a cash injection by the middle of next year, and with the remainder of its pipeline mid-stage at best, it falls to nalmefene to allow this to happen without too much pain for investors. Shares in Biotie have lost almost a third of their value this year suggesting limited confidence in success, but analysts believe a negative readout would mean further substantial falls - analysts at NomuraCode reckon a drop of more than 70% is possible; unequivocally strong results are going to be required to re-inject optimism. Product Nalmefene Company Biotie Therapies Lundbeck Market Cap $82m $3.46bn Product NPV n/a $68m NPV % of market cap n/a 2% Event Phase III data Clinical Trial IDs NCT00811720 (ESense 1); NCT00812461 (ESense 2); NCT00811941 (Sense) Date by end of 2010 Milestones Nalmefene is partnered with Lundbeck, so Biotie’s investors will not be the only ones watching for this data although in the grand scheme of things the drug is a lot of less important for the Danish partner. Still, Lundbeck has invested fairly heavily in the development of the drug – three large pivotal trials are under way, recruiting around 1,800 patients. Two identical six month trials called Esense 1 and 2, each recruiting 600 patients, are measuring efficacy. The primary endpoints are the change in the number of heavy drinking days and total alcohol consumption over 24 weeks. Another slightly larger trial called Sense which focuses on safety and tolerability is also under way. Data from this trial and one of the Esense trials are anticipated before year end. A filing with European regulators is expected in the second half of next year. Under the Lundbeck deal milestones of up to €72m ($101m) are available to Biotie on filing and approval, and ultimately royalties on sales which analysts believe are around 15%. Biotie ended June with just €12m in cash and has made it clear that by the end of the June next year, it will need to have found additional funds. Therefore a milestone payment from Lundbeck would come in very handy, although the company is also looking at licensing deals as another source of income. Remove pressure Management has said all options are on the table with regards to fundraising, which indicates tapping the equity markets is not out of the question. A standby equity agreement is already in place with Yorkville Advisors, giving access to up to €20m if required, which the company will use to keep ticking over should other sources of income fail to materialise. The company could well be hoping to use any significant jump in the share price to sell a big chunk of new shares to raise a larger amount. The real desire, however, is to raise non-dilutive funds through licensing deals. Biotie is working on two phase II pipeline projects, a PDE4 inhibitor called ronomilast and a VAP-1 antibody, BT- 1023. Partnering deals are being explored for these assets; earlier this year Roche passed on an option to fully license BT-1023, which is being developed in rheumatoid arthritis. As such, positive data on nalmefene would remove a lot of pressure from this process. Debatable value Nalmafene is an opioid receptor antagonist, thought to work by reducing the pleasure felt from addiction. Exactly how big a product it represents is debatable. Analysts at Deutsche Bank believe that because the market for pharmaceutical treatments for alcoholism is very underdeveloped, the product could struggle to generate significant sales. This theory is certainly supported by Alkermes’ experience with Vivitrol, which was approved to treat alcohol dependence in 2006 but failed to generate substantial interest – annual sales have been flat at around $20m. However, although these products are both opioid antagonists they not directly comparable; nalmefene will be used to moderate heavy drinking rather than promote abstinence, like Vivitrol. More importantly, Vivitrol is injected and has a black box warning on its label for liver toxicity, while nalmefene is a tablet, taken when a patient has a desire to drink. Whether this means nalmefene will slot more easily into programmes for alcoholics remains to be seen, but opinions of the value of the drug differ widely. Analysts at Edison Investment Research estimate peak sales of $567m whereas NomuraCode is more conservative, with peak European sales of €210m. Analysts at Jefferies, who follow Lundbeck, have only pencilled in peak sales of $55m while Deutsche Bank is forecasting only $38m by 2015. Credit Suisse is slightly more optimistic, forecasting sales of $96m by 2015. Whatever the final market value, positive data leading to a filing and approval – and all important milestone payments – are needed. Popping the champagne corks might be an inappropriate term here, but Biotie will justifiably be celebrating if strong data emerges. More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..
Load more

Recommended publications
  • Acorda Announces a Recommended Cash Tender Offer for All Shares, Adss and Other Equity Instruments in Biotie
    NEWS RELEASE Acorda Announces a Recommended Cash Tender Offer for All Shares, ADSs and Other Equity Instruments in Biotie 1/19/2016 ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (“Acorda”) and Biotie Therapies Corp. (“Biotie” or the "Company") have today entered into a combination agreement ("Combination Agreement") whereby Acorda, either directly or through a wholly-owned subsidiary (jointly the "Offeror"), will make a public tender offer in Finland and in the United States to purchase all of the issued and outstanding shares, American Depositary Shares ("ADSs"), stock options, share units and warrants in Biotie that are not owned by Biotie or any of its subsidiaries (the “Tender Offer”). The price offered for each share validly tendered into the Tender Offer will be EUR 0.2946 in cash, representing a premium of approximately 95 per cent compared to the closing price of the Biotie shares on Nasdaq Helsinki Ltd. (“Nasdaq Helsinki”) on 18 January 2016, the last trading day on Nasdaq Helsinki preceding this announcement. This represents a premium of approximately 84 per cent compared to the 3 month volume-weighted average trading price on Nasdaq Helsinki and approximately 56 per cent compared to the 6 month volume-weighted average trading price on Nasdaq Helsinki. The price offered for each ADS will be EUR 23.5680 in cash, payable in the equivalent amount of U.S. dollars determined as near to the payment date as reasonably practicable based on the U.S. dollar spot rate against the euro exchange rate on the nearest practicable day to the closing date of the Tender Offer.
    [Show full text]
  • Biotie Therapies Annual Report 2006
    Annual Report 2006 Biotie Therapies Contents President’s Review 2 Partnering Agreements 3 Information for Shareholders 4 Management Team 7 Research and Product Development 8 Projects: Nalmefene for dependence disorders 10 Partnering agreements for nalmefene 12 First-in-class therapeutics for inflammatory diseases 14 Two innovative therapeutics for thrombosis 16 Corporate Governance 18 Board of Directors 20 Report from the Board of Directors 21 Financial Statements Consolidated Income Statement, IFRS 26 Consolidated Balance Sheet, IFRS 26 Shareholders’ Equity Statement, IFRS 27 Consolidated Cash Flow Statement, IFRS 27 Notes to the Consolidated Financial Statements 28 Parent Company Income Statement, FAS 40 Parent Company Balance Sheet, FAS 40 Parent Company Cash Flow Statement, FAS 41 Notes to the Parent Company Financial Statements 41 Signatures, Report from the Board of Directors and Financial Statements 46 Auditors’ Report 46 Main Stock Exchange Releases in Brief 47 Formulas for the Calculation of the Financial Ratios 48 Key Figures 49 First-in-class pharmaceuticals BioTie in Brief 1 The year 2006 in brief The 2006 financial statement has been prepared in accordance with IFRS recognition and measurement Nalmefene for alcoholism VAP-1 therapeutics for inflam- In November, BioTie and H. Lundbeck A/S signed an agreement on worldwide rights for nalmefene, principles, and applying the same accounting policy Marketing Authorisation matory diseases excluding North America, Mexico, UK, Ireland, Turkey, as for the 2005 financial statements. Application submitted in the UK and South Korea which have already been licensed. The net loss in financial year 2006 stood at EUR First-in-class In total, BioTie is eligible for up to EUR 88 million in –9.0 million (in 2005 EUR –7.9 million).
    [Show full text]
  • Biotie Interim Report 1 January - 31 March 2012
    Source: Biotie Therapies May 04, 2012 02:00 ET Biotie Interim report 1 January - 31 March 2012 BIOTIETHERAPIESCORP.StockExchangeRelease4May,2012at 9.00a.m. BiotieInterimreport1January-31March2012 BiotiereportsQ12012results;clinicaldevelopmentremainsontrack,with importantinflectionpointsexpectedinH22012andbeyond CompanyHighlights *SuccessfullycompletedaclinicalPETimagingstudywithSYN120 *PartnerLundbeckpresenteddataatthe2012EuropeanCongressofPsychiatry showingthatSelincroreducestotalalcoholconsumptionbytwo-thirdson averageaftersixmonthsoftreatment,furtherdatatobepresentedata medicalconferenceinthesummer *PanuMiettinenappointedChiefFinancialOfficer(CFO)andamemberofthe Group'smanagementteam,effectiveMarch15,2012 KeyFinancialsfortheperiodendingMarch31,2012 Figuresinbrackets,unlessotherwisestated,refertothesameperiodinthe previousyear(EURmillion) *RevenuesEUR0.0million(0.5) *ResearchanddevelopmentcostsEUR5.8million(4.9) *FinancialResult(Netloss)EUR-7.5million(-7.7) *Cashflowfromoperatingactivities,continuingoperationsEUR-9.3million (-4.2) *LiquidassetsattheendofperiodEUR24.7million(46.8) *Earningspershare-0.02(-0.03) Theinterimreportisunaudited.Liquidassetsarecomprisedofcash,cash equivalentsandinvestmentsheldtomaturity. TimoVeromaa,Biotie'sPresidentandCEOcommented,"Weareverypleasedwith theprogressofourclinicalstudies.Withourleadasset,Selincro,under reviewattheEuropeanMedicinesAgencywithourpartnerLundbeck,ourfocusis ondrivingforwardthenextwaveofproductsinourpipeline,forwhichwecould seeanumberofimportantdatapointsinthenext12-18months". Outlookfor2012andkeyupcomingmilestonesin2012
    [Show full text]
  • Biotie Therapies Annual Report 2003
    Annual Report 2003 Contents Information for Shareholders .......................................................3 BioTie in Brief ................................................................................4 The Year 2003 in Brief....................................................................5 President’s Review..........................................................................7 Business Model ...............................................................................8 Vision...............................................................................................9 Strategy...........................................................................................9 Research and Product Pipeline...................................................10 Nalmefene.....................................................................................12 VAP-1 as Target Molecule for Drug Development....................14 Other Research Projects .............................................................16 Network of Scientifi c Collaboration ..........................................18 Board of Directors .......................................................................20 Management Team.......................................................................20 Human Resources ........................................................................21 Report from the Board of Directors ..........................................22 Income Statement .......................................................................26 Balance
    [Show full text]
  • March 31, 2003
    BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 28.4.2003 at 8.30 am INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 – MARCH 31, 2003 • In January 2003, BioTie sold its process development and manufacturing unit as part of the company’s strategy to focus on drug development. • The operating profit (loss) for the first quarter was EUR –4.3 million (in 2002, EUR –6.0 million pro forma). • The company’s liquid assets amounted to EUR 5.4 million (in 2002, EUR 9.0 million pro forma) at March 31, 2003. • After the reporting period, the company completed the first phase III clinical studies of the nalmefene tablet intended for the treatment of alcoholism. • In April 2003, the National Technology Agency (Tekes) made a conditional grant of additional funding of EUR 5.9 million for the company’s research and development programs. • After the reporting period, the company entered into a licensing agreement on the company’s VAP-1 antibody program worth USD 16.7 million with the Japanese Seikagaku Corporation. The agreement will enter into force when BioTie has completed the new issue currently being prepared and secured funding for its operations until the end of 2004. The agreement grants BioTie a signing fee of USD 2.5 million. • On April 28, 2003, The Board of Directors of BioTie Therapies decided on preparations to arrange a new issue whereby the shareholders of the company would have the pre-emptive subscription right for the new shares. With the new issue the company aims to raise EUR 10-14 million new capital primarily from company’s current shareholders by the end of June 2003.
    [Show full text]
  • Biotie Therapiesannual Report 2004
    Annual Report 2004 CONTENTS 3 Information For Shareholders 4 BioTie In Brief 7 President’s Review 8 Partnering Status 10 Research And Product Development 12 Dependence Disorders 14 VAP-1 Anti-infl ammatory Target 16 Other Research Projects 18 Integrin Inhibitors 19 Board of Directors / Management 20 Network of Scientifi c Collaboration 21 Patents 22 Report From The Board Of Directors 26 Income Statement 27 Balance Sheet 28 Cash Flow 29 Notes To Financial Statements 35 Auditor’s Report 36 Key Figures 37 Formulas For The Calculation Of The Financial Ratios 38 Share Capital And Shares 40 Main Stock Exchange Releases In 2004 In Brief 41 Business Model 42 Glossary 2 Information for Shareholders ANNUAL GENERAL MEETING The Annual General meeting of Biotie Therapies Corp. will be held on Wednesday March 30, 2005 commencing at 14.30 (2.30 p.m.), at the Mauno Koivisto Center in Turku (Tykistökatu 6). Shareholders are entitled to participate in the Annual General Meeting if they are registered in the Company’s register of shareholders maintained by the Finnish Central Securities Depository Ltd no later than March 18, 2005. Shareholders wishing to participate in the Annual General Meeting must notify the Company thereof no later than March 24, 2005 at 16.00 (4.00 p.m.) either in writing to Biotie Therapies Corp., Ms Virve Nurmi, Tykistökatu 6, FIN-20520 Turku, Finland, or by telephone at +358 2 274 8911 during office hours 9.00–16.00 from Monday to Friday. The letter of participation must arrive at the Company before the expiry of the above mentioned period for notification.
    [Show full text]
  • Financial Results for the Second Quarter of Fiscal Year 2010
    Exploring the Innovative Promise of Glycoscience Financial Results for the 1H of FY2010 (April 1, 2010-September 30, 2010) （TSE：4548） 1 Financial results for 1H FY2010 (Comparison with 1H FY2009 and initial forecast) (Millions of Yen) vs. Initial vs. Initial FY 2010 FY 2009 Previous Forecast for Forecast 1H Results 1H Results Period 1H for 1H Net Sales 13,882 13,965 -83 14,000 -117 （-0.6%） （-0.8%） Operating 1,799 2,862 -1,062 2,100 -300 Income （-37.1%） （-14.3%） Ordinary 1,717 2,790 -1,073 2,200 -482 Income （-38.5%） （-21.9%） -716 Net Income 1,178 1,894 1,500 -321 （-37.8%） （-21.5%） R&D 3,484 2,703 +781 3,100 +384 Expenses （-28.9%） （+12.4%） R&D Expenses Ratio （to Net Sales） 25.1% 19.4% +5.7pt 22.1% +3.0pt Net Income per Share ¥20.74 ¥33.35 -¥12.61 ¥26.40 -¥5.66 Average exchange rate for ¥88.95 ¥95.50 ¥92.00（ Forecast） period（1US$） 2 Net Sales for 1st Half of FY2010 (Year ending March 2011) Net sales: ¥13,882 million (-¥83 mil./-0.6%) (Year-on-year Comparison) [Pharmaceuticals: ¥11,054 million (+¥181 mil.)] - Domestic (+¥755 mil.) Growth in ARTZ sales outweighed the effect of reduced NHI reimbursement price. - Overseas (-¥573 mil.) U.S.: Sales lower due to lower volumes resulting from tightening of reimbursement criteria by some private health insurers, and due to high yen China: Sales higher because of increased local sales. Negative impact of one-time royalty revenue in 2009/1H [Fine chemicals: ¥2,828 million (-¥264 mil.)] Research reagents and diagnostics (-¥17 mil.): Impact of high yen and lower domestic sales (ACC sales higher in local currency) Active pharmaceutical ingredients (-¥247 mil.): Shipments of hyaluronic acid postponed to 3rd quarter or later ◆Point: Net sales were close to the level of the previous year.
    [Show full text]
  • Biotie Interim Report Q1 2014
    BIOTIE THERAPIES CORP. INTERIM REPORT 31 October, 2014 at 9.00 a.m. Biotie interim report 1 January – 30 September 2014; Company Highlights July - September 2014 • Preparations to advance tozadenant into Phase 3 development in Parkinson’s disease as part of Biotie’s proprietary portfolio continued during the quarter and it is expected that the Phase 3 program will be able to start recruiting patients during H1 2015, as planned. • The formal transfer process of global rights to tozadenant from UCB Pharma S.A. (UCB) to Biotie was concluded in August. The transfer agreement confirms that UCB will meet all its contractual and scientific commitments regarding the ongoing development program for tozadenant, which are expected to be fully completed by the end of 2014. • Biotie was awarded a USD 2.0 million (approximately EUR 1.6 million) grant from The Michael J. Fox Foundation (MJFF) to investigate SYN120 in a Phase 2 study in Parkinson's disease dementia, further strengthening Biotie's presence in the Parkinson's disease space. The study is currently expected to begin recruitment around the end of 2014. • A Phase 2 clinical study with Biotie's BTT1023 in primary sclerosing cholangitis (PSC) was awarded external grant funding of up to approximately EUR 1.0 million from the Efficacy and Mechanism Evaluation (EME) Programme funded and managed by the National Institute for Health Research (NIHR) in the UK. The study will be conducted in partnership with the University of Birmingham and is expected to start recruiting patients by the end of 2014. • Biotie´s partner H. Lundbeck A/S (Lundbeck) continued the rollout of Selincro in European markets, and it has now been introduced in well over 20 European markets, including the five key markets for which Biotie received a launch milestone.
    [Show full text]
  • ACORDA THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-50513 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3831168 (State or other jurisdiction of incorporation (I.R.S. Employer or organization) Identification No.) 420 Saw Mill River Road, Ardsley, New York 10502 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (914) 347-4300 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock $0.001 par value NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: none Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in rule 405 of the Securities Act. Yes ☒ no ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ no ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Study Protocol Tozadenant TOZ-CL05, Amendment No
    Study No. TOZ-CL05 1 of 15 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 Study No. TOZ-CL05 ing Study No. TOZ-CL05 Study No. TOZ-CL05 . Biotie Therapies FINAL, 13 October 2017 Clinical Study Protocol Tozadenant TOZ-CL05, Amendment No. 3 CLINICAL STUDY PROTOCOL Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End-of-Dose “Wearing-Off” (TOZ-PD) Protocol Number TOZ-CL05 (FINAL, 13 October 2017) Phase 3 IND Number 78,230 EudraCT Number 2014-005630-60 Date of Amendment 3 13 October 2017 Date of Amendment 2 10 June 2015 Date of Amendment 1 19 May 2015 Original Date of Issue 30 March 2015 Sponsor Biotie Therapies (a wholly owned subsidiary of Acorda Therapeutics Inc.) 701 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 USA Confidential Material THIS PROTOCOL IS THE PROPERTY OF BIOTIE THERAPIES INC (COLLECTIVELY WITH ITS AFFILIATES AND PARENT INCLUDING BIOTIE THERAPIES AG AND BIOTIE THERAPIES HOLDING AG AND BIOTIE THERAPIES CORP, “COMPANY”) AND IS A CONFIDENTIAL COMMUNICATION. ACCEPTANCE IMPLIES AN AGREEMENT NOT TO DISCLOSE INFORMATION CONTAINED HEREIN THAT IS NOT OTHERWISE PUBLICLY AVAILABLE, EXCEPT FOR USE BY AN INSTITUTIONAL REVIEW BOARD (IRB)/INDEPENDENT ETHICS COMMITTEE (IEC) FOR THE PURPOSE OF OBTAINING APPROVAL/FAVORABLE OPINION TO CONDUCT THE STUDY.
    [Show full text]
  • Biotie Therapies Corp. Stock Exchange Bulletin 1(14) 24 January at 9.00 A.M
    BIOTIE THERAPIES CORP. STOCK EXCHANGE BULLETIN 1(14) 24 JANUARY AT 9.00 A.M. FINANCIAL STATEMENT BULLETIN OF BIOTIE THERAPIES CORP., JANUARY 1 - DECEMBER 31, 2001 The year 2001 in brief · BioTie signed a collaboration agreement with Shimizu Pharmaceutical, a member of Takeda Group, on the development of BioHeparin for the Japanese hemodialysis market. · Regulatory authorities in an EU member country gave a positive opinion to start clinical studies with Bioheparin. · The first phase I/II clinical trials in BioTie’s VAP-1 antibody therapy program were completed. · The development schedule of the second generation VAP-1 antibody drug Huvap has been accelerated by approximately six months. · Small molecule VAP-1 SSAO inhibitor (Vapill) has been shown to be efficacious in animal models of rheumatoid arthritis. · The National Technology Agency (Tekes) granted 3.4 million euros additional funding for BioTie’s drug development projects. · A court ruling in the patent dispute with Orion Corporation is expected during the first quarter of 2002. The Company believes that Orion’s claims are without merit and is defending it’s patent’s vigorously. · Operating profit (loss) amounted to EUR –10.2 million (EUR –6.9 million in 2000). Research and Development investments increased by 63 %. · Cash and cash equivalents amounted to EUR 9.5 million on 31.12.2001 Review of 2001 operations BioTie is a drug development biotech company focusing on inflammation, thrombosis and cancer. Operations are conducted in collaboration with leading academic institutions, clinical research organizations and contract manufacturers. Drug Development Projects VAP-1 antibody therapy program The first phase I/II clinical trials in BioTie’s VAP-1 antibody therapy program were completed during the financial year.
    [Show full text]
  • BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer))
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BIOTIE THERAPIES OYJ (Name of Subject Company (Issuer)) ACORDA THERAPEUTICS, INC. (Name of Filing Person (Offeror)) Ordinary shares, no nominal value (“Ordinary Shares”) American Depositary Shares (“ADSs”), each representing 80 ordinary shares, no nominal value Option rights issued under the December 6, 2011 option plan (“2011 Option Rights”) Option rights issued under the January 2, 2014 option plan (“2014 Option Rights”) Option rights issued under the January 4, 2016 option plan (“2016 Option Rights”) Share units issued under the December 6, 2011 equity incentive plan (“2011 Share Rights”) Share units under the January 2, 2014 equity incentive plan (“2014 Share Rights”) Option rights awards under the Swiss option plan dated June 18, 2008 (“Swiss Option Rights”) Warrants issued on May 28, 2015 (“Warrants”) (Title of Class of Securities) FI0009011571 (Ordinary Shares) 09074D103 (ADSs) None (2011 Option Rights) None (2014 Option Rights) None (2016 Option Rights) None (2011 Share Rights) None (2014 Share Rights) None (Swiss Option Rights) None (Warrants) (CUSIP Number of Class of Securities) Jane Wasman President, International, General Counsel and Corporate Secretary Acorda Therapeutics, Inc. 420 Saw Mill River Road Ardsley, NY 10502 (914) 347-4300 (Name, address and telephone number of person authorized to receive notices and communications on behalf of filing person) Copy to: Daniel Wolf, P.C. Kirkland & Ellis LLP 601 Lexington Ave New York, NY 10022 (212) 446-4884 CALCULATION OF FILING FEE Transaction valuation(1) Amount of filing fee(2) $367,900,597.37 $37,047.59 (1) Calculated solely for purposes of determining the filing fee.
    [Show full text]